Metformin off label
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Off-Label Uses of Metformin: A Comprehensive Overview
Metformin for Polycystic Ovary Syndrome (PCOS)
Metformin is widely recognized as an off-label treatment for polycystic ovary syndrome (PCOS). It is primarily used to improve insulin sensitivity in women with PCOS, which can help regulate menstrual cycles and reduce androgen levels. However, its use is often limited by gastrointestinal side effects. A meta-analysis comparing metformin with myo-inositol, another treatment for PCOS, found no significant differences in fasting insulin, HOMA index, testosterone, SHBG levels, or BMI between the two treatments. However, metformin was associated with a higher risk of adverse events, making myo-inositol a more tolerable option for some women.
Metformin in Type 1 Diabetes
Although primarily used for type 2 diabetes, metformin is also used off-label in type 1 diabetes to reduce insulin requirements and improve glucose control, particularly in overweight and obese patients. Recent findings from the REMOVAL trial suggest that metformin can reduce the progression of atherosclerosis, lower weight, and decrease LDL-cholesterol levels in type 1 diabetes patients. These benefits indicate a potential role for metformin in reducing long-term cardiovascular risks in this population.
Metformin for Obesity and Insulin Resistance in Adolescents
Metformin is frequently used off-label to treat obesity and insulin resistance in adolescents. A long-term study showed that metformin, combined with lifestyle interventions, helped stabilize BMI and improve body composition in obese, insulin-resistant adolescents. The study found significant reductions in fat mass and HbA1c levels, suggesting that metformin can be an effective adjunct therapy for this demographic. However, another study indicated that while metformin-naive participants initially saw decreases in BMI and HOMA-IR, these effects were not sustained over prolonged use, possibly due to compliance issues or insufficient dosing.
Metformin for Weight Gain in Autism Spectrum Disorder
Metformin has also been used off-label to manage weight gain induced by atypical antipsychotic medications in children and adolescents with autism spectrum disorder. A study involving a 16-week open-label extension found that metformin effectively reduced BMI z-scores and maintained prior weight loss achieved during an initial randomized clinical trial. This suggests that metformin can be beneficial for managing antipsychotic-induced weight gain in this population.
Metformin in Cancer Prevention and Treatment
Emerging evidence suggests that metformin may have potential as an anticancer agent. Population studies have indicated that metformin use is associated with lower cancer incidence and mortality rates in diabetic patients. The drug's mechanisms of antitumor activity are becoming better understood, and it is being explored as a potential adjunct to chemotherapy or targeted therapy in cancer treatment.
Metformin for Other Conditions
Metformin is also used off-label for various other conditions, including steatohepatitis, HIV-associated metabolic abnormalities, and even as an anti-aging agent. Its broad range of applications highlights its versatility and potential beyond its primary use as an antidiabetic medication.
Conclusion
Metformin's off-label uses span a wide range of conditions, from PCOS and type 1 diabetes to obesity, autism spectrum disorder, and even cancer. While it offers significant benefits in these areas, its use is often accompanied by adverse effects, particularly gastrointestinal issues. Therefore, the decision to use metformin off-label should be carefully considered, weighing the potential benefits against the risks.
Sources and full results
Most relevant research papers on this topic